[Lamivudine therapy for chronic hepatitis B].
Daikoku
Manabu
M
Division of Viral Hepatitis, Clinical Research Center, National Nagasaki Medical Center.
Koga
Michiaki
M
D020816:Amino Acid Motifs / Q000235:genetics; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D015415:Biomarkers / Q000097:blood; D004261:DNA Replication / Q000187:drug effects; D004279:DNA, Viral / Q000097:blood; D003845:Deoxycytosine Nucleotides / Q000378:metabolism; D003864:Depression, Chemical; D024882:Drug Resistance, Viral / Q000235:genetics; D006515:Hepatitis B virus / Q000187:drug effects / Q000201:enzymology / Q000235:genetics / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D009154:Mutation; D012194:RNA-Directed DNA Polymerase / Q000737:chemistry; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D015415:Biomarkers; D004279:DNA, Viral; D003845:Deoxycytosine Nucleotides; D018894:Reverse Transcriptase Inhibitors; C024107:2'-deoxycytidine 5'-triphosphate; D019259:Lamivudine; D012194:RNA-Directed DNA Polymerase